High mutation load, defined as > 100 nonsynonymous single-nucleotide variants (nsSNV) per exome, was associated with clinical benefit in melanoma patients treated with anti-CTLA‐4 therapy [51, 52]. This evidence concerns the gene CTLA4 and melanoma.